BURTON UPON TRENT, England–(BUSINESS WIRE)–Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare and fatal genetic condition of accelerated aging …